LMDX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (4 bal. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	120.55M
Średni wolumen	0.00
Kapitalizacja rynkowa	249.63M
EPS	$0 ( 2024-03-19 )
Następna data zysków	( $0 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0100
ATR14	$0.0140 (93.33%)

Wolumen Korelacja

Długi: 0.04 (neutral)

Krótki: -0.37 (neutral)

Signal:(34.365) Neutral

LumiraDx Limited Korelacja

10 Najbardziej pozytywne korelacje
RMRM	0.966
CRGE	0.948
BCAN	0.939
CNEY	0.93
ADMP	0.921
JWEL	0.918
CVAC	0.909
LGVN	0.908
RIDE	0.907
BROG	0.905

10 Najbardziej negatywne korelacje
KEQU	-0.945
RNLC	-0.931
FRG	-0.92
PTMN	-0.919
SGII	-0.905
IMPP	-0.902
KRUS	-0.901
INBKZ	-0.9
VMGA	-0.898
AEAE	-0.895

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

LumiraDx Limited Korelacja - Waluta/Towar

-0.74
( moderate negative )

-0.81
( strong negative )

0.00
( neutral )

-0.62
( weak negative )

-0.64
( weak negative )

0.55
( weak )

LumiraDx Limited Finanse

Annual	2022
Przychody:	$254.48M
Zysk brutto:	$-35.30M (-13.87 %)
EPS:	$-1.590

FY	2022
Przychody:	$254.48M
Zysk brutto:	$-35.30M (-13.87 %)
EPS:	$-1.590

Financial Reports:

No articles found.

LumiraDx Limited

LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has approximately 30 tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions from the lab to point of need. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company was founded in 2014 and is headquartered in London, the United Kingdom.